Selected Toxicities of Targeted Therapies: Presentation and Management

被引：7
|
作者：
Kollmannsberger, Christian [1 ]
Mitchell, Teresa [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Canc Ctr, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
SEMINARS IN ONCOLOGY | 2013年 / 40卷 / 04期
关键词：
RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; SUNITINIB; EFFICACY; HYPERTENSION; EVEROLIMUS; TEMSIROLIMUS; BEVACIZUMAB;
D O I：
10.1053/j.seminoncol.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：499 / 510
页数：12
相关论文
共 50 条
  • [31] Targeted therapies for renal cell carcinoma
    Villanueva, Mary Lee H.
    Hauke, Ralph
    TARGETED ONCOLOGY, 2007, 2 (01) : 7 - 16
  • [32] Targeted therapies for renal cell carcinoma
    Mary Lee H. Villanueva
    Ralph Hauke
    Targeted Oncology, 2007, 2 : 7 - 16
  • [33] Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
    Tan, Xiaojie
    Liu, Yan
    Hou, Jianguo
    Cao, Guangwen
    ONCOTARGETS AND THERAPY, 2015, 8 : 313 - 321
  • [34] Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects
    Davin, Jean-Louis
    Ducrotte, Philippe
    Houede, Nadine
    BULLETIN DU CANCER, 2011, 98 : S69 - S78
  • [35] Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
    Hutson, Thomas E.
    ONCOLOGIST, 2011, 16 : 14 - 22
  • [36] Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies
    Escudier, Bernard
    Osanto, Susanne
    Ljungberg, Borje
    Porta, Camillo
    Wagstaff, John
    Mulders, Peter
    Gore, Martin
    Bex, Axel
    Bellmunt, Joaquim
    Bracarda, Sergio
    Franklin, Alex
    Honore, Per Hartvig
    Ravaud, Alain
    van Steijn, Jeanne
    Aziz, Zeba
    Akaza, Hideyuki
    CANCER TREATMENT REVIEWS, 2012, 38 (02) : 127 - 132
  • [37] Targeted therapies in metastatic renal cancer in 2009
    Bastien, Laurence
    Culine, Stephane
    Paule, Bernard
    Ledbai, Souhil
    Patard, Jean Jacques
    de la Taille, Alexandre
    BJU INTERNATIONAL, 2009, 103 (10) : 1334 - 1342
  • [38] Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
    Viswanath Reddy Belum
    Andrea Cercek
    Virginia Sanz-Motilva
    Mario E. Lacouture
    Current Treatment Options in Oncology, 2013, 14 : 389 - 404
  • [39] Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders
    Caron, Philippe
    Gravis, Gwenaelle
    Oudard, Stephane
    Pignot, Geraldine
    BULLETIN DU CANCER, 2011, 98 : S47 - S59
  • [40] Targeted Agents: Management of Dermatologic Toxicities
    Burtness, Barbara
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (5.5): : 793 - 796
12345